Wall Street analyst estimates for Greenwich LifeSciences, Inc. (GLSI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials.
Valuation Ratios
| Price / Book | 71.02 |
| EV / EBITDA | -10.05 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $3607 | $3607 | $3607 | $3609 | $3612 | $3612 | $3612 | $3612 | $1779 |
| Gross Profit | -$3607 | -$3607 | -$3607 | -$3609 | -$3612 | -$3612 | -$3612 | -$3612 | -$1779 |
| Research & Development | $1.2M | $1.3M | $2.6M | $1.1M | $3.6M | $6.5M | $7.7M | $15.5M | $17.2M |
| Selling, General & Admin | $346812 | $419639 | $818887 | $806188 | $1.0M | $1.6M | $1.6M | $2.2M | $2.2M |
| Operating Expenses | $1.6M | $1.7M | $3.4M | $1.9M | $4.6M | $8.0M | $9.3M | $17.6M | $19.4M |
| Operating Income | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$8.0M | -$9.3M | -$17.6M | -$19.4M |
| EBITDA | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M |
| Income Tax | $3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M |
| EPS | $-0.13 | $-0.14 | $-0.29 | $-0.15 | $-0.35 | $-0.61 | $-0.69 | $-1.21 | $-1.43 |
| EPS (Diluted) | $-0.13 | $-0.14 | $-0.29 | $-0.15 | $-0.35 | $-0.61 | $-0.69 | $-1.21 | $-1.43 |
| Shares Outstanding (Diluted) | $11.7M | $12.0M | $11.7M | $12.7M | $12.9M | $12.9M | $12.8M | $13.0M | $13.5M |
Price
| Price | $15.63 |
| Market Cap | $229M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AGEN · ATOS · CGTX · HURA · IMMX · IRD · ONCY
Explore sector: Healthcare · Biotechnology
More sections of GLSI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks